Neuren Pharmaceuticals welcomes milestone approval for Daybu
Neuren Pharmaceuticals has received positive news for the proposed marketing of the Daybu treatment of Rett syndrome.
Market Cap $276.6M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 10.43am 29/06/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 70.5¢ | Day High | 72.5¢ | Day Low | 70.5¢ | |||
| Daily Volume | 189308 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 71.5¢ | 36943 | 0 | 72.5¢ | 83951 | |
Directors & Senior Management
| Mr. Birol Akdogan | Interim Chief Financial Officer |
| Ms. Catherine Ann Aston | Independent Non-Executive Director |
| Ms. Catherine Jane West | Independent Non-Executive Director |
| Dr. Deirdre Zander-Fox | Chief Scientific Officer |
| Dr. E.N. Dwayne Crombie | Independent Non-Executive Director |
| Dr. Fleur Cattrall | Chief Medical Officer |
| Mr. Neil John Broekhuizen | Independent Non-Executive Director |
| Ms. Niki Howells-Schramm | Chief People Officer |
| Ms. Rebecca Dean | Company Secretary & General Counsel |
| Ms. Rebecca Redden | Chief Operating Officer |
| Dr. Richard Charles Henshaw | Executive Director |
| Mr. Richard Hugh Davis | Independent Non-Executive Chairman |
| Ms. Tedd Fuell | Chief Governance & Risk Officer |
| Dr. Victoria Atkinson | MD, CEO & Director |
| Ms. Zita Peach | Independent Non-Executive Director |
Data source: ADVFN
